Clinical Trials Logo
  1. Home
  2. Colorectal Adenocarcinoma
  3. NCT03708536

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Colorectal Adenocarcinoma Clinical Trial

Official title:
Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma. A Phase 3 Randomised Controlled Trial

Clinical Trial Summary

Bevacizumab plus capecitabin is a standard maintenance treatment following first-line chemotherapy in the patients with advanced colorectal adenocarcinoma. However, hand-foot syndrome induced by capecitabin will bother the patient to decrease the quality of life. S-1, an alternative of fluoropyrimidine, was proved non-inferior efficacy with lower hand-foot syndrome as first-line chemotherapy in advanced colorectal adenocarcinoma in the studies. The investigators are going to test the efficacy and safety of bevacizumab plus S-1 as maintenance treatment compared with bevacizumab plus capecitabin in colorectal adenocarcinoma

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03708536
Study type Interventional
Source Fujian Cancer Hospital
Contact
Status Withdrawn
Phase Phase 3
Start date November 2018
Completion date November 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04094688 - Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer Phase 3
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT06050447 - Factors Affecting the Results of Treatment of Patients With Colorectal Cancer
Recruiting NCT05504252 - METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin Phase 2
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT00597506 - Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Phase 2
Recruiting NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer Phase 1/Phase 2
Completed NCT05477836 - Feasibility and Safety of MiWEndo-assisted Colonoscopy N/A
Recruiting NCT05620134 - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer Phase 1/Phase 2
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Recruiting NCT04870879 - Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors N/A
Recruiting NCT04773769 - Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas N/A
Recruiting NCT04739072 - Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Recruiting NCT06134440 - ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study N/A
Withdrawn NCT02413853 - Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer Phase 2
Completed NCT00165217 - Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Phase 2
Active, not recruiting NCT04457284 - Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer Phase 2
Suspended NCT04111172 - A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma Phase 2
Not yet recruiting NCT06118658 - Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations Phase 2
Completed NCT00593060 - Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer Phase 1